CLOs on the Move

Nautilus Biosciences Canada

www.nautilusbiosci.com

 
Nautilus Biosciences Canada is a Charlottetown, PE-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Similar Companies

Center for Autism and Related Disorders

The Center for Autism and Related Disorders, Inc.

LTS LOHMANN Therapy-Systems

LTS offers a wealth of experience in adhesive formulation and coating technology to manufacture and supply specialty laminates intermediates for many applications. Our products are tailored to our customers' needs and are targeted for use in

Breckenridge Pharmaceutical

Breckenridge Pharmaceutical Inc. is a Boca Raton, FL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Refresh Mental Health

Refresh Mental Health is the parent company of premiere outpatient mental health, substance abuse & eating disorder practices across the United States.

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.